Her research is
currently studying programs that provide services to promote parent education and employment to improve family well - being.
Not exact matches
She taught environmental
studies at Dartmouth University and is
currently the lead ambassador for Bayer's science literacy
program Making Science Make Sense.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other
programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance
Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its
currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines
currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory
programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
programs; safety and efficacy data from clinical
studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase
program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Bernanke had presided over the United States central bank during the 2008 - 09 international financial crisis and is
currently a distinguished fellow in residence with the economic
studies program at the Brookings Institution.
While industry partners have come together to fund various
studies with regard to sustainability and water efficiency, one of the most promising
programs currently in the works is in the Peanut Genome Initiative.
He is
currently an adjunct professor in the Security
Studies Program at Georgetown University's Edmund A. Walsh School of Foreign Service.
Currently I'm
studying in a part - time career counseling
program at a local university and working part - time at the church.
Currently, the largest of these
programs is the Tennessee - based Weigh Down Workshop (founded in 1986), a 12 - week Bible
study program that is now offered in as many as 10,000 churches in the U.S. and elsewhere.
Resources they
currently use: If the individual has some books that they constantly use, as part of their Bible
study, then I write them down, and match them to the packages offered for the various
programs.
A
study by researchers at the University of Michigan [15] views such suggestions as having «merit,» noting that, while sensors may
currently be beyond the reach of most football
programs, a «number of companies are developing innovative, low - cost technologies that will make instrumentation both practical and feasible.»
More organizations in Great Britain are supportive and Canadian provinces are
currently transitioning to midwifery, said
study lead author Patricia Janssen, director of the Master of Public Health
Program at the University of British Columbia.
Currently, he is undertaking
studies at Chalmers University of Technology in Gothenburg, Sweden in MPALG (Masters
Program in Algorithms, Logic & Languages).
After the business roundtable meeting, the Governor participated in a walking tour of Old Havana, which included a viewing of an antique car and a brief meeting with students from the State University of New York system who are
currently studying in Cuba as part of exchange
programs.
She
currently teaches at the Center for Curatorial
Studies, Bard College, and is a board member of Primary Information and Dirty Looks; Advisory Board Member of the Outpost Cuts and Burns Residency
Program and John Kelly Performance; and recipient of a Skowhegan Governors» Award for Outstanding Service to Artists and the inaugural White Columns / Shoot the Lobster Award.
The science
program currently supports a wide area of research, including airborne measures of Alaska's interior forests, prototype methane monitors for California regulators, satellite - based assessments of farming emissions, and
studies of forest fires in the Amazon basin.
We are
currently working with Linda Bradley, Ph.D., professor in the Immunity and Pathogenesis
Program, and co-author of the
study, to couple our approach with an approach to reining in the autoimmune response,» added Levine.
The
study, «AKR1B1 promotes basal - like breast cancer progression by a positive feedback loop that activates the EMT
program,» which has been published in The Journal of Experimental Medicine, suggests that an inhibitor of this enzyme
currently used to treat diabetes patients could be an effective therapy for this frequently deadly form of cancer.
«There is
currently no method that can predict treatment outcome of chemotherapy early on in treatment, so this is a major advance,» says Hielscher, co-leader of the
study, who is also a member of the Breast Cancer
Program at the Herbert Irving Comprehensive Cancer Center at NewYork - Presbyterian / Columbia University Irving Medical Center.
DEQ will also be
studying how a cap - and - trade
program would interact with existing
programs, including the state's renewable portfolio standard, its clean fuels
program and U.S. EPA's Clean Power Plan for power plants, which is
currently on hold pending court challenges.
«In
studying one of the most dramatic episodes of global change since the end of the age of the dinosaurs, these scientists show that we are
currently in uncharted territory in the rate carbon is being released into the atmosphere and oceans,» says Candace Major,
program director in the National Science Foundation (NSF)'s Division of Ocean Sciences, which funded the research.
Currently, the agency's National Research Service Award (NRSA) training
program gives grants to universities to help roughly 7000 graduate students a year pursue multidisciplinary
studies.
Hopefully, this internship may turn out to be a
program for future science assistants at NSF like the fieldwork I'm
currently participating in with Dr. Jim Harvey and his
studies on harbor seals.
Support for the seminar series, including refreshments and travel, lodging, and honorarium gifts for the speakers, is provided by the Alabama National Science Foundation Experimental
Program to Stimulate Competitive Research (EPSCoR) and Oak Ridge Associated Universities Visiting Industrial Scholars ProgramThe UAB Graduate Student Association, the UAB Graduate School, and the UAB Office of Postdoctoral
Studies currently support special activities such as Career Day.
An initiative of the Reebok Foundation, which was a co-sponsor of the current
study, the BOKS
Program is
currently available in more than 3,000 elementary and middle schools in the U.S. and other countries.
The family in this
study has received genetic counseling through the St. Jude Cancer Predisposition
Program to understand the risk and the need for continued monitoring, particularly of the
currently cancer - free child with the ETV6 variation.
Over that time, the BCI
program has seen four graduate students earn degrees from the Department of Electrical and Computer Engineering at UBC, with four more
currently still
studying.
This
study, reported in a special issue of LSE, was led by Rebekah L. Layton in the UNC Office of Graduate Education and principal investigator Melanie Sinche, formerly of the Labor & Worklife
Program at Harvard Law School,
currently with The Jackson Laboratory.
The research centre
currently consists of seven groups
studying epigenetic mechanisms regulating cellular differentiation
programs.
Claire is
currently a PhD candidate in the Molecular and Cellular Biology
Program at the University of Washington, where she
studies the patterning and development of the nervous system, using genetic and bioinformatic approaches.
Matt Boersma»04 Honors student with Seth Ramus, now at Johns Hopkins University, graduate student in Neuroscience Scott Herrick»04 Honors student with Seth Ramus, now at Rockefeller University, technician in the lab of Bruce McEwen Emily Thompkins»03 Tufts University School of Veterinary Medicine Alexis Goldstein»03 Independent
Study Research with Seth Ramus, now at The Pacific College of Oriental Medicine, graduate student Christopher Johnson»03 Laboratory technician at Brandeis University Kirsten George»03 Laboratory technician at Bowdoin (in professor thompson's lab) Kelly Dakin»02
Currently in the neuroscience grad
program at Harvard Tyler Dunphee»02
Currently in medical school at U. Minnesota Lauren Axelrod»02
Currently in medical school at University Wisconsin Yen Wing Chu»01
Currently in the neuroscience grad
program at Johns Hopkins Channing Paller»01
Currently an MD / PhD student at Harvard Shiva Gupta»01
Currently in Med School at New York Medical College Andrew Evans»01
Currently in the neuroscience grad
program at U. Bristol in England Shawn Pelletier»01
Currently in pharmacology grad
program at University Connecticut
Isabel Low is
currently a second year PhD student in Stanford's Neuroscience Graduate
Program,
studying how our brain helps us navigate through space.
She's
currently in her third year at USC majoring in Health Promotion and Disease Prevention with a minor in Health Care
Studies and in the Global Medicine masters
program.
That obligation, combined with the education and training he received by participating in the Health Board's environmental health
program, convinced Carlisle that Church Rock Chapter needed to conduct its own environmental monitoring to generate new data that would be used to estimate population exposures, plan future health
studies, and most important, determine if lands
currently occupied and those slated for residential development - like Springstead - are safe for human habitation.
He served as director of graduate
studies for the
program in spring, 2013, and is
currently a visiting research fellow at Merton College at the University of Oxford.
The institute's extramural
program that Dr. Guyer
currently directs annually distributes more than $ 350 million in research and training grants and cooperative agreements, and plans a wide range of scientific activities to advance genomics, including
studying the societal implications of genomics research.
We also describe
currently available in vitro assays to
study each step of the BM transmigration
program.
He
currently serves as the center PI for the National Standards for Fetal Growth
study as well as the PI for the Environmental influences on Child Health Outcomes (ECHO)
program.
Nearly 60 genetics education
programs worldwide
currently use the textbook, in levels ranging from undergraduate to graduate and professional
study, and in diverse contexts including medical, nursing, public health, speech and language, and dental
programs.
Ms. Miller is
currently the Deputy Executive Director for
Programs and Finance at the Society for Neuroscience (SfN), a professional society of basic scientists and physicians who
study the brain and nervous system.
«With this (technology), the center will provide the biology research community with tools to
study an enormous number of biological systems that are
currently inaccessible by current X-ray methods,» says NSF Chemistry of Life Processes
Program Manager David Rockcliffe.
She considers herself a lifelong student and is continuing her
studies through Spira's 500 hr teacher training
program modules and is
currently focused on exploring &
studying a wide range of meditation techniques.
Regarding exercise
programs: Unlike other online coaches that do some photoshoots, get «internet famous,» and decide they are qualified to prescribe training to other people — I've
studied hard to become a NASM certified personal trainer and am
currently in a graduate
program at the University of South Florida to earn a Master's of Science degree in Exercise Science with a focus on Strength and Conditioning.
Those who wish to focus on an area of integrative healthcare not
currently offered as part of a formalized
program of
study through HUHS should consider the personalized concentration.
She graduated from the YogaWorks 200 hour teacher training
program under Annie Carpenter and Birgitte Kristen in 2010, and is
currently studying with Jay Co in the YogaCo teacher training
program based in Santa Monica.
Mandolin
currently attends the University of New Mexico, where she
studies in the Interdisciplinary Film and Digital Media
Program with a concentration in Directing and Writing.
In recent UNHCR
study conducted in two camps, refugees stated needs for livelihoods
programs that are in fact already running
currently (LWG Working Group Meeting 2011).
As a result of such endeavors, UT
currently boasts one of the largest
study abroad
programs in the nation.
The Daily News cited a new
study by Rachel Cole, James Kemple, and Micha Segeritz of the Research Alliance for New York City Schools that reported that School of One had produced modest results at the three middle schools
currently implementing the model as the regular in - school math
program in its first year.
Now along come high quality IES
studies of
programs that feature most of the elements
currently thought to characterize top notch professional development
programs.
Currently 75 afterschool
program sites also participate in the Youth Program Quality Intervention (YPQI) study from the national Center for Youth Program Q
program sites also participate in the Youth
Program Quality Intervention (YPQI) study from the national Center for Youth Program Q
Program Quality Intervention (YPQI)
study from the national Center for Youth
Program Q
Program Quality.